clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Discitis D015299 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Iritis D007500 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Fractures, Open D005597 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Ecchymosis D004438 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Parotitis D010309 4 associated lipids
Cysts D003560 4 associated lipids
Psittacosis D009956 4 associated lipids
Prurigo D011536 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Duodenitis D004382 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Ergotism D004881 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Gu LK et al. [Effect of selenium-enriched garlic on chronic gastritis of the glandular stomach of Mongolian gerbils induced by H. pylori]. 2007 Zhonghua Yu Fang Yi Xue Za Zhi pmid:17767872
Lo WC et al. Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. 1997 Zhonghua Yi Xue Za Zhi (Taipei) pmid:9198292
Huang WH et al. New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. 1998 Zhonghua Yi Xue Za Zhi (Taipei) pmid:9745160
Cheng H et al. [Influence of resistance of Helicobacter pylori to antibiotics on the Helicobacter pylori eradication regimens]. 2006 Zhonghua Yi Xue Za Zhi pmid:17199976
Cheng H and Hu FL [The epidemiology of Helicobacter pylori resistance to antibiotics in Beijing]. 2005 Zhonghua Yi Xue Za Zhi pmid:16324315
Zheng XL and Xu L [Efficacy of second-line treatment based on moxifloxacin triple therapy for Helicobacter pylori infection]. 2010 Zhonghua Yi Xue Za Zhi pmid:20356487
Cheng H et al. [Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study]. 2010 Zhonghua Yi Xue Za Zhi pmid:20356486
Hu FL [A multicenter study of Chinese patent medicine wenweishu/yangweishu in the treatment of Helicobacter pylori positive patients with chronic gastritis and peptic ulcer]. 2010 Zhonghua Yi Xue Za Zhi pmid:20356485
Chai D et al. [Effect of macrolides on biofilm of mucoid Pseudomonas aeruginosa]. 2001 Zhonghua Yi Xue Za Zhi pmid:11702671
Meng X et al. [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. 2016 Zhonghua Yi Xue Za Zhi pmid:26879786
Hu FL et al. [Jinghuaweikang capsules combined with triple therapy in the treatment of Helicobacter pylori associated gastritis and duodenal ulcer and analysis of antibiotic resistance: a multicenter, randomized, controlled, clinical study]. 2012 Zhonghua Yi Xue Za Zhi pmid:22781295
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study]. 2004 Zhonghua Yi Xue Za Zhi pmid:15387976
Zheng XL et al. [Genotypic homogeneity and susceptibility to clarithromycin for clarithromycin-resistant Helicobacter pylori strains]. 2009 Zhonghua Yi Xue Za Zhi pmid:19953885
Zou J et al. [Laboratory and clinical study of levofloxacin against Helicobacter pylori]. 2003 Zhonghua Yi Xue Za Zhi pmid:14642083
Zheng X et al. [The prevalence and mechanism of Helicobacter pylori resistance to clarithromycin in Beijing]. 2001 Zhonghua Yi Xue Za Zhi pmid:11930609
Zheng X et al. [The resistance of Helicobacter pylori toward metronidazole and clarithromycin]. 2001 Zhonghua Yi Xue Za Zhi pmid:11769712
Chen B et al. [Pulmonary disease caused by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation--a case report and literature review]. 2004 Zhonghua Xue Ye Xue Za Zhi pmid:15555262
He XX et al. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese]. 2004 Zhonghua Nei Ke Za Zhi pmid:14990013
Wang LJ et al. [The effects of Helicobacter pylori infection on hyperammonaemia and hepatic encephalopathy in cirrhotic patients]. 2006 Zhonghua Nei Ke Za Zhi pmid:17074151
Zhang L et al. [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection]. 2015 Zhonghua Nei Ke Za Zhi pmid:26887366
Chen S et al. [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592303
Liu W et al. [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592304
Gui J et al. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. 2013 Zhonghua Jie He He Hu Xi Za Zhi pmid:24252731
Lu Y et al. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis]. 2010 Zhonghua Jie He He Hu Xi Za Zhi pmid:21092635
Nie W et al. [The analysis of species identification and susceptibility testing of Mycobacterium abscessus]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262693
Duan HF et al. [Susceptibility test of the Mycobacterium avium complex to sixteen anti-infective agents]. 2010 Zhonghua Jie He He Hu Xi Za Zhi pmid:20646615
Zhao C et al. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012]. 2015 Zhonghua Jie He He Hu Xi Za Zhi pmid:25791651
Chen PR and Tan SY [The treatment outcomes of 21 cases of rapidly growing mycobacteria related pulmonary disease]. 2013 Zhonghua Jie He He Hu Xi Za Zhi pmid:23856140
Fu Y et al. [The effect of interventional therapy in multimodality treatment on multi-drug resistant pulmonary tuberculosis]. 2008 Zhonghua Jie He He Hu Xi Za Zhi pmid:18683778
Weng KR et al. [Treatment and a follow-up study on wound infection by Mycobacterium chelonae: report of 168 cases]. 2004 Zhonghua Jie He He Hu Xi Za Zhi pmid:15196343
Gui J et al. [Subspecies identification for Mycobacterium abscessus group]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262692
Sun H et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014]. 2016 Zhonghua Jie He He Hu Xi Za Zhi pmid:26792053
Wang H et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. 2012 Zhonghua Jie He He Hu Xi Za Zhi pmid:22455967
Yan WH et al. [Rapid detection of clarithromycin resistant Helicobacter pylori from children's gastric biopsy specimens by polymerase chain reaction-restriction fragment length polymorphism]. 2009 Zhonghua Er Ke Za Zhi pmid:20078998
Yan WH et al. [Preliminary study on in-vitro induction of antibiotic resistance in Helicobacter pylori strains isolated from children]. 2007 Zhonghua Er Ke Za Zhi pmid:18021568
Hua CZ et al. [Serotypes and antibiotics-resistance patterns of 247 strains of Haemophilus Influenzae isolated from children in Hangzhou]. 2004 Zhonghua Er Ke Za Zhi pmid:15631716
Chen J et al. [Prevalence of Helicobacter pylori resistant to clarithromycin, amoxicillin and metronidazole in children]. 2004 Zhonghua Er Ke Za Zhi pmid:16221349
Chen XX et al. [Long-term therapeutic effect of triple therapy consisted of omeperazole, clarithromycin and amoxycillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment]. 2004 Zhonghua Er Ke Za Zhi pmid:15265423
Huang J et al. [A 10-day sequential therapy for eradication of Helicobacter pylori infection in children]. 2012 Zhonghua Er Ke Za Zhi pmid:23158730
Chen J et al. [Prevalence and mechanism of Helicobacter pylori resistance to clarithromycin in children]. 2004 Zhonghua Er Ke Za Zhi pmid:15631715
Yang H et al. [Macrolide-resistant Streptococcus pneumoniae in the pediatric population in Beijing]. 2004 Zhonghua Er Ke Za Zhi pmid:15733368
Wang Y et al. [Analysis of the infection status and the drug resistance of mycoplasma and chlamydiae in genitourinary tracts of children with suspected nongonococcal urethritis]. 2009 Zhonghua Er Ke Za Zhi pmid:19573386
Luo Q et al. [Clinical effect of clarithromycin therapy in patients with chronic rhinosinusitis]. 2014 Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi pmid:24742507
Guo SB et al. [Preparation and identification of the oligonucleotide chip for detecting the virulence-associated genotypes and drug resistance of Helicobacter pylori]. 2007 Zhongguo Yi Xue Ke Xue Yuan Xue Bao pmid:17380677
Yang CS et al. [Study of correlation between Helicobacter pylori infection and hyperammonemia and hepatic encephalopathy in cirrhotic patients]. 2007 Zhongguo Wei Zhong Bing Ji Jiu Yi Xue pmid:17631712
Zhao HM et al. [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children]. 2014 Zhongguo Dang Dai Er Ke Za Zhi pmid:24661511
Huang LP et al. [Antimicrobial resistance of 36 strains of Helicobacter pylori in adolescents]. 2009 Zhongguo Dang Dai Er Ke Za Zhi pmid:19292962
Xiang L et al. [Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children]. 2007 Zhongguo Dang Dai Er Ke Za Zhi pmid:17582255
Wang F et al. [Five-day rabeprazole-based triple therapy for helicobacter pylori infection]. 2004 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:16137055
Li Y et al. [Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication]. 2008 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:19141980
Wu S et al. [Anti-Helicobacter pylori treatment in patients with idiopathic thrombocytopenic purpura]. 2009 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:20045922
Wang F et al. [Antibiotic resistance of Helicobacter pylori]. 2007 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:17611323
Li F et al. [Effect of prokinetic agents on the electrical activity of stomach and duodenum in rats]. 2009 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:19648670
Tang D et al. [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment]. 2018 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:30124214
Tu S and Yang H [Progress in the treatment of Helicobacter pylori infection]. 2014 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:25269503
Gamova NA [Drug sensitivity of Ureaplasma urealyticum, persisting in patients with chronic inflammatory diseases of the urogenital tract]. 2003 Jul-Aug Zh. Mikrobiol. Epidemiol. Immunobiol. pmid:12966887
Fabry W et al. Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium tuberculosis. 1995 Zentralbl. Bakteriol. pmid:9810662
Alter P et al. [Impediment of cellular immune response under treatment with ticlopidine in a patient with Staphylococcus aureus endocarditis]. 2000 Z Kardiol pmid:11013974
Knothe H [Short-term therapy of acute respiratory and ORL infections with Clarithromycin]. 1992 Z Gesamte Inn Med pmid:9022402
Hellmeyer L et al. [Q Fever in pregnancy: a case report and review of the literature]. 2002 Sep-Oct Z Geburtshilfe Neonatol pmid:12395293
Knippig C et al. Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up. 2002 Z Gastroenterol pmid:12055660
Lüth S et al. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study. 2001 Z Gastroenterol pmid:11367976
Fritzsch J et al. [Eosinophilic gastritis after helicobacter pylori eradication]. 2008 Z Gastroenterol pmid:19053006
Bayerdörffer E [The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol]. 2000 Z Gastroenterol pmid:10689750
Schepp W [Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori]. 1995 Z Gastroenterol pmid:7502558
Regnath T et al. [Real-time PCR assay for rapid detection of clarithromycin-resistant helicobacter pylori in gastric biopsy specimens]. 2004 Z Gastroenterol pmid:15592960
Stolte M et al. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. 1998 Z Gastroenterol pmid:9773482
Labenz J and Stolte M [Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. 1999 Z Gastroenterol pmid:10458014
Schilling D et al. [Eradication of helicobacter pylori: symptomatic treatment of reflux disease?]. 2002 Z Gastroenterol pmid:12122605
Krasz S et al. [Current value of quinolones in Helicobacter pylori therapy]. 2011 Z Gastroenterol pmid:21811951
Bojarski C et al. Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. 2000 Z Gastroenterol pmid:10768243
Schütze K and Hentschel E Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. 1995 Z Gastroenterol pmid:8600661
Tillenburg B et al. [Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)]. 1997 Z Gastroenterol pmid:9173687
Lee SH et al. Sequential bilateral lung resection in a patient with Mycobacterium abscessus lung disease refractory to medical treatment. 2010 Yonsei Med. J. pmid:20046529
Jun HJ et al. Successful treatment of Mycobacterium celatum pulmonary disease in an immunocompetent patient using antimicobacterial chemotherapy and combined pulmonary resection. 2010 Yonsei Med. J. pmid:20879072
Chang JH et al. A case of acute hepatitis with Mycoplasma pneumoniae infection and transient depression of multiple coagulation factors. 2008 Yonsei Med. J. pmid:19108034
Koh H et al. Nodular gastritis and pathologic findings in children and young adults with Helicobacter pylori infection. 2007 Yonsei Med. J. pmid:17461522
Tsai SH et al. Hypoglycemia revisited in the acute care setting. 2011 Yonsei Med. J. pmid:22028152
Kwon YS et al. Solitary pulmonary nodule due to Mycobacterium intracellulare: the first case in Korea. 2007 Yonsei Med. J. pmid:17326256
Park HK et al. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. 2010 Yonsei Med. J. pmid:20499421
Hatipoglu ON and Tasan Y A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. 2000 Yonsei Med. J. pmid:10957888
Sim YS et al. Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. 2010 Yonsei Med. J. pmid:20879056
Jeen YT et al. Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis. 2001 Yonsei Med. J. pmid:11293500
Lee KY et al. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease. 2008 Yonsei Med. J. pmid:18306487
Chin BS et al. The characteristics of metallo-β-lactamase-producing gram-negative bacilli isolated from sputum and urine: a single center experience in Korea. 2011 Yonsei Med. J. pmid:21319358
Park HY et al. Pulmonary disease caused by Mycobacterium xenopi: the first case in Korea. 2007 Yonsei Med. J. pmid:17963348
Qin LH and Tang X [Preparation and evaluation of clarithromycin emulsion for injection]. 2006 Yao Xue Xue Bao pmid:17184111
Zhang T et al. [Preparation and evaluation of enteric-coated and taste masking clarithromycin granules]. 2011 Yao Xue Xue Bao pmid:22375429
Ma HL et al. [Polarographic catalytic wave of clarithromycin and its applications]. 2004 Yao Xue Xue Bao pmid:15700824
Wang J et al. [Different concentrations of clarithromycin ophthalmic gel for rabbits corneal ulcers induced by Staphylococcus aureus]. 2008 Yan Ke Xue Bao pmid:18709951
Vakil N Treatment of H. pylori infection: the reality. 1998 Mar-Apr Yale J Biol Med pmid:10378357
Niioka T Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors. 2011 Yakugaku Zasshi pmid:21372537
Suzuki A et al. [Clinical efficacy of kanamycin for Mycobacterium avium complex disease]. 2008 Yakugaku Zasshi pmid:18311066
Matsuo R et al. [Bitterness of the mixture of clarithromycin dry syrup and carbocisteine preparation--difference between brand name and generic drugs]. 2008 Yakugaku Zasshi pmid:18311069
Omura S et al. [Research and development of clarithromycin]. 1992 Yakugaku Zasshi pmid:1469609
Salimi A et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. 2016 Xenobiotica pmid:26068526
Pan W et al. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. 2013 Xenobiotica pmid:22830954
Kanayama N et al. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. 2007 Xenobiotica pmid:17484517
Kubo JI et al. Pharmacokinetic evaluation of high pulmonary disposition of clarithromycin after systemic administration. 2002 Xenobiotica pmid:12419017
Yamamoto T et al. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. 2005 Xenobiotica pmid:16192112